Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

The subdued stock price reaction suggests that Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) strong earnings didn't offer any surprises. We think that investors have missed some encouraging factors underlying the profit figures.

Zooming In On Gulf Pharmaceutical Industries P.S.C's Earnings

Many investors haven't heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company's profit is backed up by free cash flow (FCF) during a given period. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF.

Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.

For the year to December 2024, Gulf Pharmaceutical Industries P.S.C had an accrual ratio of -0.11. That implies it has good cash conversion, and implies that its free cash flow solidly exceeded its profit last year. In fact, it had free cash flow of د.إ192m in the last year, which was a lot more than its statutory profit of د.إ14.7m. Gulf Pharmaceutical Industries P.S.C shareholders are no doubt pleased that free cash flow improved over the last twelve months.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Gulf Pharmaceutical Industries P.S.C.

Our Take On Gulf Pharmaceutical Industries P.S.C's Profit Performance

As we discussed above, Gulf Pharmaceutical Industries P.S.C has perfectly satisfactory free cash flow relative to profit. Based on this observation, we consider it likely that Gulf Pharmaceutical Industries P.S.C's statutory profit actually understates its earnings potential! And it's also positive that the company showed enough improvement to book a profit this year, after losing money last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So while earnings quality is important, it's equally important to consider the risks facing Gulf Pharmaceutical Industries P.S.C at this point in time. While conducting our analysis, we found that Gulf Pharmaceutical Industries P.S.C has 1 warning sign and it would be unwise to ignore it.

Today we've zoomed in on a single data point to better understand the nature of Gulf Pharmaceutical Industries P.S.C's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.